期刊文献+

儿茶酚-O-甲基转移酶抑制剂临床应用进展 被引量:7

Current Clinical Progress of COMT Inhibitor
原文传递
导出
摘要 多巴胺(DA)是脑内重要的神经递质,参与调控椎体外系的运动功能以及人类的精神活动,情绪反应,认知、思想、感觉、理解和推理能力。多巴胺在各条通路的增多或减少可以导致各种疾病。儿茶酚-O-甲基转移酶(COMT)参与代谢降解多巴胺。COMT抑制剂可以减慢DA的代谢,且可以延长左旋多巴(L-dopa)在体内的半衰期,达到治疗由于DA减少的相关疾病。COMT抑制剂主要有托卡朋和恩他卡朋,两者分别在1997年和1998年由FDA首次批准上市。2004年,由卡比多巴、左旋多巴和恩他卡朋组成的复方制剂Sta levo被重新投放市场。本文总结了COMT抑制剂目前在临床上的应用进展,如协助治疗帕金森病,抗抑郁,抗Ⅱ型精神失常和治疗神经痛。 Dopamine (DA) is an important brain neurotransmitter, which involved in the regulation of extrapyramidal motor fun- ction, as well as human mental activity, emotional response, cognition, thinking, feeling, understanding and reasoning ability. The increa- se or decrease of Dopamine in each pathway can lead to various diseases. Catechol-O-methyl transferase (COMT) is involved in the met- abolic degradation of dopamine. COMT inhibitors can reduce the degradation of DA, and also can be extended to levodopa (L-dopa) half-life in vivo, so as to achieve treatment due to reduction of DA related diseases. COMT inhibitors include tolcapone and entacapone, respectively in 1997 and 1998 by FDA first approved listing. Carbidopa, levodopa and entacapone compounded preparation composed as Sta levo was back on the market in 2004. This paper summarizes current clinical progress of COMT inhibitor, such as assisting the treatment of Parkinson's disease, anti-depression, anti-schizophrenia and the treatment of neuralgia.
出处 《现代生物医学进展》 CAS 2014年第5期982-985,共4页 Progress in Modern Biomedicine
基金 上海市自然科学基金(12ZR1415700) 上海市重点学科开放课题(S30201) 国家"重大新药创制"科技重大专项(2009ZX09301-007)
关键词 多巴胺 儿茶酚-O-甲基转移酶 帕金森病 抑郁 II型精神失常 神经痛 Dopamine Catechol-O-methyl transferase Parkinson's disease Depression Schizophrenia Neuralgia
  • 相关文献

参考文献1

二级参考文献12

  • 1DINGENMANSE J. Issues important for rational COMT inhibition[ J ]. Neurology, 2000,55 ( 11 Suppl 4 ) : S24 - S27.
  • 2POEWE WH, DEUSCHL G, GORDIN A,et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response : a 6-month randomized placebo-controlled double-blind study in Germany and Austria( Celomen study) [ J ].Acta Neurol Scand, 2002,105(4) :245 -255.
  • 3REICHMANN H, BOAS J, MACMAHON D,et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. [J] Acta Neurol Scand, 2005,111 (1) :21 -28.
  • 4RINNE UK, LARSEN JP, SIDEN A, et al. The Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations [ J ]. Neurology,1998,51(5) :1309 -1314.
  • 5ONOFRJ M,THOMAS A, VINGERHOETS F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease Patients experiencing wearing-off, regardless of the dosing frequency:results of a large multicentre open-label study [J]. Neural Transm, 2004, 111 ( 8 ) :1053 - 1063.
  • 6CHONG BS, MERSFELDER TL. Entacapone[ J ]. Ann Pharmacother, 2000,9 ( 34 ) : 1056 - 1065.
  • 7RINNE UK, GORDIN A, TERAVAINEN HT. COMT inhibition with entacapone in the treatment of Parkinson's disease[ J]. Adv Neurol, 1999,80 (3) :491 - 494.
  • 8PALMER CS, NUIJTEN M J, SCHMIER JK, et al. Cost effectiveness of treatment of Parkinson's disease with entaeapone in the United States [J]. Pharmacoeconomics, 2002,20 (9) :617 - 628.
  • 9MYLLYL VV, KULTALAHTI ER, HAAPANIEMI H, et al.Twelvemonth safety of entacapone in patients with Parkinson's disease[J]. Eur J Neurol, 2001,8(1) :53 -60.
  • 10WATERS C. Practical issues with COMT inhibitors in Parkinson's disease [ J ]. Neurology, 2000,55 ( 11 Suppl 4 ) : S57 - S59.

共引文献4

同被引文献113

引证文献7

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部